Suppr超能文献

急性呼吸窘迫综合征持续肾脏替代治疗的新见解:一项系统评价和荟萃分析

New Insights on Continuous Renal Replacement Therapy for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.

作者信息

Zeng Siyao, Cui Shanpeng, Li Yue, Yao Zhipeng, Li Yunlong, Cao Yang, Wen Lianghe, Li Ming, Zheng Junbo, Wang Hongliang

机构信息

Graduate School, Harbin Medical University, Harbin, Heilongjiang, China.

Department of Critical Care Medicine, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.

出版信息

Clin Respir J. 2025 Jan;19(1):e70045. doi: 10.1111/crj.70045.

Abstract

BACKGROUND

In recent times, the applications of continuous renal replacement therapy (CRRT) beyond kidney-related conditions have been progressively increasing, and its implementation in randomized controlled trials (RCTs) specifically for acute respiratory distress syndrome (ARDS) has been documented. This meta-analysis compiles all existing RCTs to assess whether CRRT benefits ARDS.

METHODS

We searched 12 databases in English and Chinese and two clinical trial centers up to November 28, 2023. The main outcome indicator is the mortality rate. Secondary outcome indicators include incidence of ventilator-associated pneumonia (VAP), ICU length of stay, mechanical ventilation time, oxygenation index (OI) at 24 h (h), OI at 48 h, OI at 72 h, OI at 7 days (d), partial pressure of oxygen (PaO) at 72 h, Acute Physiology and Chronic Health Evaluation II (APACHE II) score at 24 h, APACHE II score at 48 h, APACHE II score at 72 h, APACHE II score at 7 d, extravascular lung water indexes (EVLWI) at 72 h, TNF-α at 24 h, TNF-α at 7 d, IL-6 at 24 h, IL-6 at 48 h, IL-6 at 72 h, and IL-6 at 7 d. Statistical measures utilized include risk ratios (RR), weighted mean difference (WMD), and 95% confidence intervals (95% CI).

RESULTS

We summarized 36 studies, including 2123 patients. It was found that for ARDS, using CRRT in addition to conventional therapy can reduce the mortality rate (I = 0%; RR: 0.40; 95% CI: 0.30-0.53; p < 0.01), the incidence of VAP (I = 0%; RR: 0.44; 95% CI: 0.33-0.59; p < 0.01), ICU length of stay, mechanical ventilation time, and EVLWI at 72 h, as well as APACHE II score, TNF-α, and IL-6 at various time points. Additionally, it can increase OI during different time intervals and PaO at 72 h.

CONCLUSIONS

Low-quality evidence suggests that compared with conventional therapy alone, the use of CRRT may be associated with a lower mortality rate, the incidence of VAP, ICU length of stay, mechanical ventilation time, EVLWI, APACHE II score, TNF-α, and IL-6 and may be related to better respiratory function. CRRT may be beneficial for ARDS patients. Future multicenter, well-designed, high-quality RCTs are needed to substantiate these findings.

摘要

背景

近年来,连续性肾脏替代疗法(CRRT)在肾脏相关疾病以外的应用逐渐增多,并且已有其在专门针对急性呼吸窘迫综合征(ARDS)的随机对照试验(RCT)中的应用记录。本荟萃分析汇总了所有现有的RCT,以评估CRRT是否对ARDS有益。

方法

截至2023年11月28日,我们检索了12个英文和中文数据库以及两个临床试验中心。主要结局指标是死亡率。次要结局指标包括呼吸机相关性肺炎(VAP)的发生率、重症监护病房(ICU)住院时间、机械通气时间、24小时(h)、48小时、72小时、7天(d)时的氧合指数(OI)、72小时时的氧分压(PaO)、24小时、48小时、72小时、7天时的急性生理与慢性健康状况评分系统II(APACHE II)评分、72小时时的血管外肺水指数(EVLWI)、24小时、7天时的肿瘤坏死因子-α(TNF-α)、24小时、48小时、72小时、7天时的白细胞介素-6(IL-6)。所采用的统计方法包括风险比(RR)、加权平均差(WMD)和95%置信区间(95%CI)。

结果

我们汇总了36项研究,包括2123例患者。结果发现,对于ARDS,在常规治疗基础上加用CRRT可降低死亡率(I² = 0%;RR:0.40;95%CI:0.30 - 0.53;p < 0.01)、VAP的发生率(I² = 0%;RR:0.44;95%CI:0.33 - 0.59;p < 0.01)、ICU住院时间、机械通气时间以及72小时时的EVLWI,以及不同时间点的APACHE II评分、TNF-α和IL-6。此外,可以提高不同时间间隔的OI以及72小时时的PaO。

结论

低质量证据表明,与单纯常规治疗相比,使用CRRT可能与较低的死亡率、VAP发生率、ICU住院时间、机械通气时间、EVLWI、APACHE II评分、TNF-α和IL-6相关,并且可能与更好的呼吸功能有关。CRRT可能对ARDS患者有益。未来需要多中心、设计良好的高质量RCT来证实这些发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed47/11695202/f5bfc86e267c/CRJ-19-e70045-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验